CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Older Adults in the Cardiac Intensive Care Unit: Factoring Geriatric Syndromes in the Management, Prognosis, and Process of Care: A Scientific Statement From the American Heart Association Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial Complete Revascularization Versus Culprit Lesion Only in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A DANAMI-3-PRIMULTI Cardiac Magnetic Resonance Substudy A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions 中国肺高血压诊断和治疗指南2018 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography Macrophage MST1/2 Disruption Impairs Post-Infarction Cardiac Repair via LTB4 Precisely Tuned Inhibition of HIF Prolyl Hydroxylases Is Key for Cardioprotection After Ischemia

Original Research30 Jul 2018 [Epub ahead]

JOURNAL:Circulation. Article Link

The Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator

A Khera , MJ Budoff , CJ O’Donnell et al. Keywords: coronary artery calcium; risk prediction

ABSTRACT


BACKGROUND - Coronary artery calcium (CAC) is a powerful novel risk indicator for atherosclerotic cardiovascular disease (ASCVD). Currently, there is no available ASCVD risk prediction tool that integrates traditional risk factors and CAC.


METHODS - To develop a CAC ASCVD risk tool for younger individuals in the general population, subjects aged 40-65 without prior CVD from three population-based cohorts were included. Cox proportional hazards models were developed incorporating age, sex, systolic blood pressure, total and HDL cholesterol, smoking, diabetes, hypertension treatment, family history of MI, high-sensitivity CRP (hs-CRP), and CAC scores (Astro-CHARM model) as dependent variables and ASCVD (non-fatal/fatal MI or stroke) as the outcome. Model performance was assessed internally, and validated externally in a fourth cohort.

RESULTS - The derivation study comprised 7382 individuals with mean age 51 years, 45% female, and 55% non-white. The median CAC was 0 (25-75th [0,9]) and 304 ASCVD events occurred in median 10.9 years of follow-up. The c-statistic was 0.784 for the risk factor model, and 0.817 for Astro-CHARM (p<0.0001). Compared with the risk factor model, the Astro-CHARM model resulted in integrated discrimination improvement (IDI=0.0252) as well as net reclassification improvement (NRI=0.121, p<0.0001). The Astro-CHARM model demonstrated good discrimination (c=0.78) and calibration (Nam-D’Agostino χ2:13.2, p=0.16) in the validation cohort (n=2057; 55 events). A mobile application and web-based tool were developed to facilitate clinical application of this tool ( www.AstroCHARM.org).

CONCLUSIONS - The Astro-CHARM tool is the first integrated ASCVD risk calculator to incorporate risk factors, including hs-CRP and family history, and CAC data. It improves risk prediction compared with traditional risk factor equations and could be useful in risk-based decision making for CV disease prevention in the middle-aged general population.